Momenta Wins Dismissal Of Blood-Clot Drug Antitrust Suit

Law360, Los Angeles (July 27, 2016, 9:43 PM EDT) -- A Massachusetts federal judge on Wednesday said that Amphastar Pharmaceuticals Inc. cannot bring federal antitrust claims against Momenta Pharmaceuticals Inc. for allegedly suppressing competition of sales of a generic blood clot drug because its alleged injury stems from a prior court-issued injunction, immunizing Momenta from suit.

Momenta and co-defendant Sandoz Inc., which together develop and manufacture enoxaparin — a generic life-saving anti-coagulant drug used in clinical settings to treat blood clots that is sold under the brand name Lovenox — are immunized from Amphastar’s antitrust claims...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.